Sucralfate Compared with Ranitidine in the Short-Term Healing of Duodenal Ulcers

Abstract

The efficacy of sucralfate (1 g four times daily) and ranitidine (150 mg twice daily) in the short-term healing of duodenal ulcers has been assessed in a randomized single-blind trial involving 104 patients with three drop-outs. The healing rate at 3 weeks of 83% for sucralfate and 84% for ranitidine improved to 96% and 92%, respectively, at 6 weeks. The difference between the two treatment groups was not statistically significant. Smoking and male sex had no influence on the healing rates. Constipation was a prominent symptom in sucralfate treatment which was otherwise a safe and effective therapy.

Teprenone, but not H2‐Receptor Blocker or Sucralfate, Suppresses Corpus Helicobacter pylori Colonization and Gastritis in Humans: Teprenone Inhibition of H. pylori‐Induced Interleukin‐8 in MKN28 Gastric Epithelial Cell Lines

“…Sucralfate is an effective, well-known cytoprotective agent for peptic ulcers, with effects comparable to those of H2-RA [35,36]. Banerjee et al have reported that 4-week treatment with sucralfate suppresses antral H. pylori colonization and gastric urease activity in patients with duodenal ulcer [37].…”

Mucosal Protecting Agents: First Choice in Uncomplicated Ulcer Disease?

“…In comparison with H2 blockers, none of the studiesof duodenal (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19) (Fig. 1) or gastric ulcer (10.…”